Private Eye

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Off-market insider buying at Liminal BioSciences (T:LMNL)

Updated Monday Nov 09, 2020 02:53 AM EDT

Thomvest Asset Management Inc., a 10% Holder, acquired 3,157,894 Common Shares on an indirect ownership basis for registered holder Structured Alpha LP at a price of $4.750USD through a prospectus or prospectus exempt offering on November 3rd, 2020. The insider also acquired 3,157,894 Warrants with an exercise price of $5.500 for five long years. This represents a $19,717,495 investment into the company's shares and an account share holdings change of 18.9%.

The stock trades in the Unites States under ticker LMNL.

Liminal BioSciences is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.

Liminal BioSciences Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing treatments for patients suffering from diseases primarily related to fibrosis, including respiratory, liver and kidney diseases. The Company operates through two segments: Small Molecule Therapeutics Segment and Plasma-derived Therapeutics Segment. The Small Molecule Therapeutics Segment is a small-molecule drug development business. Its lead small molecule product candidate is fezagepras (PBI-4050). The Plasma-derived Therapeutics Segment includes its plasma-derived therapeutics platform, which enables the development of its pipeline of biopharmaceutical candidates. Its lead plasma-derived product candidate is Ryplazim (plasminogen).

INK Edge Outlook

CONDITIONS:
Latest
6 months ago
1 year ago
Overall
N/A
Cloudy
N/A
The INK Edge Outlook is a quantitative process that ranks a stock based on our V.I.P. criteria.
View outlooks on all Canadian listed stocks at inkresearch.com.
Two-week free trial for first time users.
Go to Liminal BioSciences Inc. (LMNL)'s company page

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).

Comment On!

No Comments

Twitter

Search (past week) for $LMNL.CA

  • No tweets found

Stocktwits